0000000000033923

AUTHOR

Giandomenico Bompiani

showing 15 related works from this author

Haemorheological components in the pre-geriatric and geriatric age range in a randomly selected Western Sicily population sample (Casteldaccia study)

1993

{Received 24.8.1992; accepted 7.12.1992} On a randomly selected western Sicily population sample (Casteldac­ cia Study: 600 subjects; 300 males and 300 females) of an age range from 40 to 79 years, were determined: Haematocrit (Htc) , blood vi­ scosity, plasma viscosity, filterability of whole blood and fibrinogen. Par­ ticipation was 97%, being 582 subjects (M = 287, F = 295). All the parameters measured showed a progressive increase with age and si­ gnificant differences were found between male and female subjects: Htc and blood viscosity were higher in male subjects (p < 0.01), while plasma viscosity, whole blood filterability and fibrinogen were higher in female subjects (p < 0.05). In …

medicine.medical_specialtyPopulation samplePhysiologybusiness.industryBlood viscosityHematologyFibrinogenGastroenterologyCoronary heart diseaseSurgeryPhysiology (medical)Internal medicinemedicineRisk factorCardiology and Cardiovascular MedicinebusinessPlasma viscosityWhole bloodmedicine.drugClinical Hemorheology and Microcirculation
researchProduct

Insulin resistance and endogenous digoxin-like factor in obese hypertensive patients with glucose intolerance

1992

Hypertensive obese subjects with glucose intolerance have hyperinsulinaemia, insulin resistance and intracellular cation imbalance resulting in increased sodium content. The aim of our study was to assess in these patients plasma levels of endogenous digoxin-like factor (EDLF), an inhibitor of the sodium-pump mechanism. We studied 14 hypertensive and 12 normotensive subjects with obesity and glucose intolerance for fasting blood glucose, and plasma insulin, C-peptide and EDLF levels: the two groups were matched for age and BMI and were studied after a 2-week wash-out period from hypotensive drugs. Compared with normotensives, hypertensive subjects had higher plasma insulin levels, a greater…

Blood GlucoseMaleDigoxinmedicine.medical_specialtyEndocrinology Diabetes and Metabolismmedicine.medical_treatmentEndogenyEndogenous digoxin-like factorEndocrinologyInsulin resistanceInternal medicineDiabetes mellitusInternal MedicineHumansInsulinMedicineObesityImmunoreactive insulinC-Peptidebusiness.industryInsulinBlood ProteinsGeneral MedicineGlucose Tolerance TestMiddle AgedSaponinsmedicine.diseaseObesityCardenolidesEndocrinologyHyperglycemiaHypertensionFemaleInsulin ResistanceSodium-Potassium-Exchanging ATPasebusinessIntracellularActa Diabetologica
researchProduct

Livelli serici di insulina nel soggetto normale (Obeso e non) e nel diabetico obeso Dopo Carico Intragastrico di Aminoacidi

1968

Gli AA. hanno somministrato in 5 soggetti normali normosomici, in 5 obesi metabolicamente sani e in 5 diabetici obesi un carico intragastrico (mediante sondino) di 9 aminoacidi essenziali (arginina, fenil-alanina, valina, leucina, lisina, metionina, isoleucina, istidina, triptofano) per un totale di g 30 ed hanno valutato la risposta insulo-pancreatica. In tutti i casi di soggetti in esame si e messo in evidenza un significativo aumento dell'insulinemia, determinata con metodo radioimmunologico. Il picco insulinemico e stato di 45 ± 11 µU/ml nei normali normosomici, di 65 ± 6 µU/ml negli obesi e di 52 ± 8 nei diabetici obesi, rispettivamente a 75 mp, a 60 mp e a 105 mp. La caduta insulinemi…

chemistry.chemical_classificationmedicine.medical_specialtybusiness.industryEndocrinology Diabetes and MetabolismInsulinmedicine.medical_treatmentGeneral Medicinemedicine.diseaseAmino acidEndocrinologyEndocrinologychemistryNon obeseIntragastric administrationDiabetes mellitusInternal medicineInternal MedicinemedicinebusinessActa Diabetologica Latina
researchProduct

Improvement of fibrinolysis and plasma lipoprotein levels induced by gemfibrozil in hypertriglyceridemia.

1995

A randomized double-blind study was carried out with gemfibrozil (600 mg b.i.d.) vs placebo in 20 patients (twelve males and eight females, age 52 +/- 3 years, BMI 24.2 +/- 0.4) suffering from primary hypertriglyceridemia (Fredrickson's type IV). Each group was treated for a 12 week period with gemfibrozil (n = 10) or placebo (n = 10) patients) in a double-blind fashion. Total cholesterol, HDL-cholesterol (HDL-C) and its subfractions (HDL2-C and HDL3-C), blood glucose, Apolipoproteins A1 and B, fibrinogen, plasminogen, factor VII, t-PA:Ag and PAI activity pre- and post-venous occlusion (VO) were determined. In the gemfibrozil-treated group a significant decrease of total cholesterol and tri…

Malemedicine.medical_specialtymedicine.medical_treatmentLipoproteinsFibrinogenchemistry.chemical_compoundDouble-Blind MethodInternal medicineFibrinolysismedicineGemfibrozilHumansTriglyceridesApolipoproteins BHypertriglyceridemiaTriglycerideApolipoprotein A-Ibusiness.industryCholesterolFibrinolysisHypertriglyceridemiaReverse cholesterol transportCholesterol HDLFibrinogenPlasminogenHematologyGeneral MedicineFactor VIIMiddle Agedmedicine.diseaseEndocrinologyCholesterolchemistryTissue Plasminogen Activatorlipids (amino acids peptides and proteins)FemaleGemfibrozilbusinessLipoproteinmedicine.drugBlood coagulationfibrinolysis : an international journal in haemostasis and thrombosis
researchProduct

Effects of heparin treatment on hemostatic abnormalities in obese non-insulin-dependent diabetic patients.

1997

This study was conducted to identify the mechanisms responsible for coagulative and fibrinolytic alterations and to study the effects of a short-term treatment with low-dose heparin on hemostatic abnormalities in obese non-insulin-dependent diabetes mellitus (NIDDM) patients. Four groups of age- and sex-matched patients were studied: (1) lean nondiabetic subjects (n = 30) with a body mass index (BMI) less than 25 kg/m2 (lean control subjects), (2) obese nondiabetic subjects (n = 30) with a BMI greater than 30 kg/m2 (obese control subjects), (3) lean NIDDM patients (n = 30), and (4) obese NIDDM patients (n = 30). All subjects were tested on the following parameters: fibrinogen, factor VII, p…

Blood GlucoseMalemedicine.medical_specialtyEndocrinology Diabetes and Metabolismmedicine.medical_treatmentFibrinogenTissue plasminogen activatorBody Mass Indexchemistry.chemical_compoundEndocrinologyInternal medicineFibrinolysismedicineHumansInsulinObesityBlood CoagulationHemostasisFactor VIIbusiness.industryHeparinFibrinolysisnutritional and metabolic diseasesAnticoagulantsHeparinMiddle AgedLipidsBlood Coagulation FactorsEndocrinologychemistryDiabetes Mellitus Type 2HemostasisCase-Control StudiesFemalebusinessPlasminogen activatorBody mass indexmedicine.drugMetabolism: clinical and experimental
researchProduct

Evaluation of B-cell secretion and peripheral insulin resistance during pregnancy and after delivery in gestational diabetes mellitus with obesity

1988

Nine pregnant women with gestational diabetes mellitus (GDM) were studied. Six normal pregnant women and six normal nonpregnant women were evaluated as control groups. All the women underwent oral glucose tolerance test and glucose clamp during the third trimester of pregnancy and two months after delivery. During OGTT, glucose, C-peptide and insulin plasma levels were determined. C-peptide and insulin values in the late phase of OGTT were higher during pregnancy than after delivery in both groups. In gestational diabetic women, the M-value in the second steady-state during glucose clamp was lower than in controls, both during pregnancy and after delivery. Nevertheless, in both groups the M…

Blood GlucoseAdultmedicine.medical_specialtyEndocrinology Diabetes and Metabolismmedicine.medical_treatmentPregnancy in DiabeticsObesity; Glucose Tolerance Test; Reference Values; Humans; Diabetes Mellitus; Islets of Langerhans; Insulin; Blood Glucose; Pregnancy; Puerperal Disorders; Adult; Insulin Resistance; Female; Pregnancy in DiabeticsIslets of LangerhansEndocrinologyInsulin resistanceReference ValuesPregnancyDiabetes mellitusInternal medicineInternal MedicinemedicineDiabetes MellitusHumansInsulinObesityPregnancyGlucose tolerance testSettore MED/12 - Gastroenterologiamedicine.diagnostic_testbusiness.industryInsulinGeneral MedicinePuerperal DisordersGlucose clamp techniqueGlucose Tolerance Testmedicine.diseaseGestational diabetesEndocrinologyGestationFemaleInsulin Resistancebusiness
researchProduct

Risposta insulo-secretrice al carico endovenoso di tolbutamide

1968

Gli AA. hanno studiato il comportamento della risposta insulinemica dopo stimolazione con tolbutamide endovenosa in un piccolo gruppo di soggetti normali normosomici, obesi non diabetici e diabetici obesi. In tutti i soggetti il massimo aumento dell'insulinemia (determinata con metodo radio-immunologico) compare a 5 mp ed e maggiore negli obesi rispetto ai normali e ai diabetici. La caduta percentuale del picco insulinemico dimostra un andamento parallelo nei normali e negli obesi, mentre e molto piu lenta nei diabetici obesi. Vengono discusse le cause di questo comportamento e la natura dell'iperinsulinismo presente nell'obesita con e senza diminuita tolleranza agli idrati di carbonio.

medicine.medical_specialtybusiness.industryEndocrinology Diabetes and MetabolismInsulinmedicine.medical_treatmentGeneral Medicinemedicine.diseaseEndocrinologyEndocrinologyTolbutamideInternal medicineDiabetes mellitusInternal MedicineMedicinebusinessInsulin secretionHyperinsulinismmedicine.drugActa Diabetologica Latina
researchProduct

Changes induced by pravastatin treatment on hemostatic and fibrinolytic patterns in patients with type IIb hyperlipoproteinemia

1994

Abstract A randomized, double-blind, parallel-group study of pravastatin versus placebo was carried out for 24 weeks in 20 patients with type IIb primary hyperlipoproteinemia. Total cholesterol, triglycerides, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, blood glucose, apolipoproteins (apo) A1 and B, and lipoprotein (a) (Lp[a]) levels were determined. A venous occlusion test was also performed in all patients. Pre- and postvenous occlusion tests were determined: tissue plasminogen activator antigen (t-PA[Ag]), plasminogen activator inhibitor (PAI) activity, factor VII, fibrinogen, plasminogen, and hematocrit. Compared with placebo, pravastatin signi…

Pharmacologymedicine.medical_specialtyApolipoprotein BbiologyTriglyceridebusiness.industryCholesterolmedicine.medical_treatmentnutritional and metabolic diseasesFibrinogenchemistry.chemical_compoundEndocrinologychemistryInternal medicineFibrinolysismedicinebiology.proteinlipids (amino acids peptides and proteins)Pharmacology (medical)businessPlasminogen activatorPravastatinmedicine.drugLipoproteinCurrent Therapeutic Research
researchProduct

Coagulation, fibrinolysis and haemorheology in premenopausal obese women with different body fat distribution

1994

Recently waist/hip ratio (WHR), a marker of body fat distribution, has been described as a risk factor for cardiovascular disease (CVD). The aim of the present study was to evaluate the influence of body fat distribution on metabolic, haemostatic and haemorheological pattern in premenopausal obese women with different WHR. Fourty premenopausal obese women were subdivided into two groups, matched for age and body mass index (BMI): 20 women with abdominal obesity (WHR = 0.94 +/- 0.02) and 20 women with peripheral obesity (WHR = 0.77 +/- 0.03). Twenty nonobese women were recruited as control group. The abdominal obesity group had significantly higher blood glucose, triglycerides, total cholest…

Adultmedicine.medical_specialtymedicine.medical_treatmentFibrinogenchemistry.chemical_compoundHigh-density lipoproteinRisk FactorsInternal medicineFibrinolysismedicineHumansObesityBlood CoagulationAbdominal obesitybiologybusiness.industryCholesterolFibrinolysisFibrinogenBlood ProteinsHematologyFactor VIIBlood Viscositymedicine.diseaseLipidsObesityEndocrinologyHematocritPremenopausechemistryCardiovascular DiseasesHemorheologybiology.proteinBody ConstitutionFemaleApolipoprotein A1medicine.symptombusinessBody mass indexmedicine.drugThrombosis Research
researchProduct

Immunoregulatory T-lymphocyte subset deficiency in newly diagnosed Type 1 (insulin-dependent) diabetes mellitus

1984

Humoral and cell-mediated disorders in Type 1 (insulin-dependent) diabetes suggest that an imbalance of immunoregulatory T-cell subsets exists. In 23 newly diagnosed (onset less than 3 months) and 21 long-standing Type 1 diabetic patients, T lymphocyte subsets were analyzed using monoclonal antibodies (OKT3, OKT4, OKT8, OKM1). The newly diagnosed patients showed a reduction with a significant difference from healthy controls in total T cells (OKT3+: 58.1 +/- 8.5% versus 70.7 +/- 8.0%), helper/inducer cells (OKT4+: 33.8 +/- 7.0% versus 47.1 +/- 8.3%), suppressor/cytotoxic cells (OKT8+: 18.5 +/- 7.3% versus 32 +/- 6.8%) and monocytes (OKM1+: 11.5 +/- 3.8% versus 19.9 +/- 5.2%) (p less than 0.…

AdultMalemedicine.medical_specialtyAdolescentmedicine.drug_classT-LymphocytesEndocrinology Diabetes and Metabolismchemical and pharmacologic phenomenaNewly diagnosedBiologyMonoclonal antibodymedicine.disease_causeT-Lymphocytes RegulatoryMonocytesAutoimmunityPathogenesisIslets of LangerhansLeukocyte CountDiabetes mellitusInternal medicineInternal MedicinemedicineHumansCytotoxic T cellChildType 1 diabetesImmunologic Deficiency SyndromesAntibodies MonoclonalT-Lymphocytes Helper-InducerT lymphocytemedicine.diseaseDiabetes Mellitus Type 1EndocrinologyFemaleT-Lymphocytes CytotoxicDiabetologia
researchProduct

Leukocyte migration test (LMT) in patients with thyroid disease: the response to human thyroid subcellular fractions.

1981

The response of circulating leukocytes to thyroid subcellular fractions was investigated in 19 patients with Graves' disease, 15 patients with Hashimoto's thyroiditis, 7 patients with toxic adenoma, 19 patients with nontoxic goiter and in 10 healthy students as control subjects. For this purpose, the leukocyte migration test of Soborg and Bendixen was performed against human crude thyroid extract (CTE), cell plasma membranes, nuclei, ribosomes, mitochondria and microsomes. Our results show positive LMT against: 1) CTE in patients with Graves' disease (61 +/- 13, p less than 0.001) and Hashimoto's thyroiditis (65 +/- 11, p less than 0.001) compared to controls (90 +/- 11); 2) cell plasma mem…

AdenomaAdultMaleendocrine systemmedicine.medical_specialtyLeukocyte migrationendocrine system diseasesAdolescentEndocrinology Diabetes and MetabolismCellThyroid GlandThyroiditisEndocrinologyInternal medicinemedicineLeukocytesHumansIn patientbusiness.industryGoiterThyroid diseaseThyroidThyroiditis AutoimmuneMiddle Agedmedicine.diseaseThyroid DiseasesGraves Diseasemedicine.drug_formulation_ingredientmedicine.anatomical_structureEndocrinologyCell Migration InhibitionMicrosomeFemalebusinessThyroid extractSubcellular FractionsJournal of endocrinological investigation
researchProduct

Prevalence of residual B-cell function related to age at onset and genetic profile in newly diagnosed type I diabetics.

1987

Patients with type I (insulin-dependent) diabetes mellitus maintain B-cell function for a varying period of time after onset. This is commonly held to account for post-initial remission. To estimate residual B-cell function we measured plasma and 24-h urinary C-peptide in 68 type I diabetic patients (age range 4-35 years, within 10-180 days of the onset of symptoms, typed for HLA-A, -B, -C and DR loci. A positive correlation (r = 0.26; p less than 0.05) was found between urinary C-peptide levels and the age of the patient. The analysis of variance of urinary C-peptide values on the basis of the presence or absence of DR3 and DR4 antigens revealed that the DR3-positive patients had reduced e…

AdultMalemedicine.medical_specialtyAdolescentEndocrinology Diabetes and MetabolismUrinary systemLate onsetGastroenterologyExcretionchemistry.chemical_compoundIslets of LangerhansEndocrinologyAntigenInternal medicineDiabetes mellitusInternal MedicinemedicineHumansChildB cellC-PeptideC-peptidebusiness.industryAge FactorsGeneral MedicineHLA-DR Antigensmedicine.diseaseEndocrinologymedicine.anatomical_structureDiabetes Mellitus Type 1chemistryChild PreschoolFemaleAnalysis of variancebusinessActa diabetologica latina
researchProduct

Fibrinolysis in hypertriglyceridaemic subjects in response to venous occlusion.

1993

We have measured various fibrinolytic and coagulation parameters (t-PA antigen, PAI, fibrinogen, plasminogen and factor VII) before and after 10 min of venous occlusion in 20 hypertryglyceridaemic subjects (twelve males and eight females, age 38 +/- 4 years, body mass index 23 +/- 1.5) and 20 healthy normal subjects, matched for sex (twelve males and eight females), age (37 +/- 3.5 years) and body mass index (22.8 +/- 1.4). At rest, t-PA:Ag, PAI, fibrinogen, plasminogen and factor VII were significantly (P < 0.005) higher in hypertriglyceridaemic subjects than in normal controls. After venous occlusion, the increase in all parameters except t-PA:Ag was more marked in the patient group than …

AdultMalemedicine.medical_specialtyPathologymedicine.medical_treatmentFibrinogenHyperlipoproteinemia Type IVVeinschemistry.chemical_compoundAntigenInternal medicineOcclusionFibrinolysisPlasminogen Activator Inhibitor 1medicineHumansFactor VIIbusiness.industryFibrinolysisHypertriglyceridemiaFibrinogenPlasminogenHematologyGeneral MedicineFactor VIIMiddle Agedmedicine.diseaseConstrictionLipidsEndocrinologyApolipoproteinsCoagulationchemistryTissue Plasminogen ActivatorFemalebusinessBody mass indexmedicine.drugBlood coagulationfibrinolysis : an international journal in haemostasis and thrombosis
researchProduct

Study on maternal, fetal and amniotic prolactin in gestational diabetic women, at term.

1982

In order to determine whether prolactin secretion was affected in diabetic pregnancy, maternal, fetal and amniotic fluid prolactin (PRL) concentrations were measured in gestational non treated diabetic women at parturition. Amniotic fluid PRL levels, though higher than those in maternal and fetal serum, were significantly lower than those of the controls (p less than 0.005); no case of respiratory distress syndrome or congenital malformation was found at birth.

Adultendocrine systemmedicine.medical_specialtyAmniotic fluidAdolescentEndocrinology Diabetes and MetabolismPregnancy in DiabeticsEndocrinologyPregnancyReference ValuesInternal medicineDiabetes mellitusInternal MedicinemedicineMaternal fetalHumansFetusRespiratory distressbusiness.industryDeciduaGeneral Medicinemedicine.diseaseAmniotic FluidFetal BloodProlactinProlactinEndocrinologymedicine.anatomical_structureGestationFemalebusinesshormones hormone substitutes and hormone antagonistsActa diabetologica latina
researchProduct

Effect of gemfibrozil treatment on fibrinolysis system in patients with hypertriglyceridemia

1992

Abstract The effect of gemfibrozil on lipidic, coagulative, and fibrinolytic pattern was studied in 20 patients with primary type IV hyperlipoproteinemia. After a 4-week stabilization period during which administration of lipid-lowering drugs was stopped and an isocaloric diet (20% protein, 30% fat, and 50% carbohydrates) was prescribed, 20 patients (12 men and 8 women; mean age, 38 ± 4 years; body mass index, 23.4 ± 1.5) suffering from primary hypertriglyceridemia were included in this study and treated for a 12-week period with gemfibrozil (600 mg BID). Every 4 weeks the following parameters were checked: glycemia, triglycerides, total cholesterol, high density lipoprotein-cholesterol, to…

Pharmacologymedicine.medical_specialtyFactor VIIbusiness.industrymedicine.medical_treatmentHypertriglyceridemiaAntithrombinmedicine.diseaseFibrinogenchemistry.chemical_compoundEndocrinologychemistryHemostasisInternal medicineFibrinolysismedicineGemfibrozillipids (amino acids peptides and proteins)Pharmacology (medical)businessPlasminogen activatormedicine.drugCurrent Therapeutic Research
researchProduct